Tubulin-Targeting Chemotherapy Impairs Androgen Receptor Activity in Prostate Cancer
Top Cited Papers
Open Access
- 13 October 2010
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 70 (20), 7992-8002
- https://doi.org/10.1158/0008-5472.can-10-0585
Abstract
Recent insights into the regulation of the androgen receptor (AR) activity led to novel therapeutic targeting of AR function in prostate cancer patients. Docetaxel is an approved chemotherapy for treatment of castration-resistant prostate cancer; however, the mechanism underlying the action of this tubulin-targeting drug is not fully understood. This study investigates the contribution of microtubules and the cytoskeleton to androgen-mediated signaling and the consequences of their inhibition on AR activity in human prostate cancer. Tissue microarrays from docetaxel-treated and untreated prostate cancer patients were comparatively analyzed for prostate-specific antigen (PSA) and AR immunoreactivity. The AR transcriptional activity was determined in prostate cancer cells in vitro, based on PSA mRNA expression and the androgen response element reporter activity. The interaction of AR with tubulin was examined by immunoprecipitation and immunofluorescence. Treatment of prostate cancer patients with docetaxel led to a significant translocation of AR. In untreated specimens, 50% prostate tumor cells exhibited nuclear accumulation of AR, compared with docetaxel-treated tumors that had significantly depleted nuclear AR (38%), paralleled by an increase in cytosolic AR. AR nuclear localization correlated with PSA expression. In vitro, exposure of prostate cancer cells to paclitaxel (1 μmol/L) or nocodazole (5 μg/mL) inhibited androgen-dependent AR nuclear translocation by targeting AR association with tubulin. Introduction of a truncated AR indicated the requirement of the NH2-terminal domain for AR-tubulin interaction. Our findings show that in addition to blocking cell division, docetaxel impairs AR signaling, evidence that enables new insights into the therapeutic efficacy of microtubule-targeting drugs in prostate cancer. Cancer Res; 70(20); 7992–8002. ©2010 AACR.Keywords
Other Versions
This publication has 40 references indexed in Scilit:
- Inhibition of the Androgen Receptor as a Novel Mechanism of Taxol Chemotherapy in Prostate CancerCancer Research, 2009
- Role of androgens and the androgen receptor in epithelial‐mesenchymal transition and invasion of prostate cancer cellsThe FASEB Journal, 2009
- Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate CancerScience, 2009
- Survival Following Primary Androgen Deprivation Therapy Among Men With Localized Prostate CancerJAMA, 2008
- Tubulin modifications and their cellular functionsCurrent Opinion in Cell Biology, 2008
- Androgen receptor as a licensing factor for DNA replication in androgen-sensitive prostate cancer cellsProceedings of the National Academy of Sciences, 2006
- HYPOGONADISM AND METABOLIC SYNDROME: IMPLICATIONS FOR TESTOSTERONE THERAPYJournal of Urology, 2005
- Expression profiling of androgen-dependent and -independent LNCaP cells: EGF versus androgen signallingEndocrine-Related Cancer, 2005
- Sexual Differentiation of the Surge Mode of Gonadotropin Secretion: Prenatal Androgens Abolish the Gonadotropin-Releasing Hormone Surge in the SheepJournal of Neuroendocrinology, 1996
- Peptide growth factors in the prostate as mediators of stromal epithelial interactionBritish Journal of Urology, 1996